Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments

Project description

A broad-spectrum treatment for viral infections

The COVID-19 pandemic highlighted the unmet medical need for new antivirals that can help tackle existing and emerging viral infections. Funded by the European Innovation Council, the FLUIDITY project proposes to develop an innovative oral small molecule that limits internalisation and intracellular trafficking of viruses. The underlying concept is based on interfering with host membrane fluidity, which is beneficial as it has a broad-spectrum effect against multiple viruses. The molecule has also demonstrated an immunomodulatory effect, preventing the immune system from reacting excessively after infection. As human safety has been validated, the project is now accelerating its clinical development.

Objective

Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses. By acting on cell membranes fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses. This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks. Moreover, our agent has immunomodulatory effects enabling to efficiently manage viral diseases by preventing excessive immune system reactions.
We will perform an accelerated development process as our molecule has already proved it safety in humans. COVID-19 will be the first demonstrator of our molecules efficacy, before targeting diseases induced by other coronaviruses, influenza, flaviviruses.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

MELETIOS THERAPEUTICS
Net EU contribution
€ 2 500 000,00
Address
13 RUE MONSIGNY
75002 Paris
France
SME
Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 582 237,50